Speaker Profile
Director, Business Development, CosmosID
Biography
Formerly the Co-Founder & Director of the Microbiome Movement Series at Hanson Wade, Mo has led the global pharmaceutical market segment at CosmosID since 2018. His role involves the support of R&D scientists and biotech executives in deploying microbial genomics throughout the drug development pipeline, including pre-clinical, clinical and CMC applications. Mo has led a number of partnerships and collaborations with big pharma, biotech and CRO’s in the incorporation of metagenomics in phase I, II and III clinical trials for the purpose of developing novel therapeutics and diagnostics.
Microbial Profiling Showcase:
CosmosID
CosmosID® is a global leader in supporting the pharmaceutical sector with CLIA-certified, ICH-GCP compliant microbiome and microbial isolate solutions for applications such as pre-clinical, clinical, CMC and regulatory support.
Supporting Drug Development with Microbiome Solutions
Robust, standardised, and validated workflows are crucial for controlling the introduction of bias. Deriving clinically actionable and informative results from shotgun metagenomic sequencing data requires modern bioinformatics and database solutions to accurately delineate microbial communities down to strain-level.
Session Abstract – PMWC 2022 Silicon Valley
Track Chair:
Rita Colwell, Johns Hopkins Bloomberg School of Public Health
Manoj Dadlani, CosmosID
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.
-
Sessions:
- Intro and Overview to Microbiome
- Manoj Dadlani, CosmosID - Pharma Drug Development (PANEL)
Session Chair: Karim Dabbagh, Second Genome
- Jennifer Wortman, Seres Therapeutics
- Paul Garofolo, Locus Biosciences
- Rangaprasad Sarangarajan, Metabolon - AI in Microbiome
- Agnieszka Piotrowska, Ardigen
- Direct-To-Consumer Testing/Technologies (PANEL)
Session Chair: Nathan D. Price, Thorne HealthTech
- Kiran Krishnan, Microbiome Labs
- Nicole Scott, Cybele Microbiome
- Noosheen Hashemi, January AI - The Role of the Human Gut Microbiome on Various Diseases
- Colleen Cutcliffe, Pendulum Therapeutics
- Tor Savidge, Baylor College of Medicine
- Nikole Kimes, Siolta Therapeutics
- Susan Lynch, UCSF - The Gut/Brain Microbiome
- Mary Conrad, Axial Biotherapeutics
- Christopher Reyes, Bloom Science
- Evolutionary Biology of the Skin Microbiome
- Larry Weiss, Symbiome - Showcase
- Heloise Breton, DNA Genotek
- Nathan Price, Thorne HealthTech
- Mo Langhi, CosmosID
- Rangaprasad Sarangarajan, Metabolon
